. Author manuscript; available in PMC: 2019 Oct 15.

Published in final edited form as: Clin Cancer Res. 2018 Sep 11;24(20):5012–5017. doi: 10.1158/1078-0432.CCR-18-0939

Table 3.

Treatment comparison by neurotoxicity status among patients treated on acute lymphoblastic leukemia protocols, 2012-2017

	Mean (95% CI) Treatment Comparison by Neurotoxicity
	Neurotoxicity (n=28)	No Neurotoxicity (n=181)	p-val

IV MTX Dose, g/m²	10.23 (8.33-12.13)	12.04 (11.37-12.71)	0.084
Number IT MTX Doses	8.84 (8.36-9.33)	11.09 (10.92-11.26)	<0.01
Time to Maintenance, days	296.9 (284.8-311.9)	290.0 (284.8-295.3)	0.408

Model adjusted for treatment risk arm, age at diagnosis, BMI z-score at diagnosis, and sex